Company: ARTL
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001640334-25-001629
Chunk: 30

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 30
---
 & Co., Inc. as the sole book running manager. The underwriter named below has agreed to purchase from us, on a firm commitment basis, the number of shares of common stock and/or Pre-funded Warrants set forth opposite its name below, at the public offering price, less the underwriting discount set forth on the cover page of this prospectus supplement.

| Name of Underwriters      |     | Number of  shares of common stock |         |     | Number of Pre-funded Warrants |        |
| R.F. Lafferty & Co., Inc. |     |                                   | 640,924 |     |                               | 40,894 |
| Total                     |     |                                   | 640,924 |     |                               | 40,894 |

The Underwriting Agreement provides that the underwriter is obligated to purchase all of the shares of common stock and/or Pre-funded Warrants offered by this prospectus supplement, other than those covered by the over-allotment option, if any shares of common stock are purchased. The underwriter is offering the shares when, as and if issued to and accepted by it, subject to a number of conditions. These conditions include, among other things, the requirements that no stop order suspending the effectiveness of the registration statement be in effect and that no proceedings for this purpose have been initiated or threatened by the SEC. Furthermore, pursuant to the Underwriting Agreement, the underwriter’s obligations are subject to customary conditions, representations and warranties contained in the Underwriting Agreement, such as receipt by the underwriter of officers’ certificates and legal opinions.

Over-allotment Option

We have granted a 45-day option to the underwriter, exercisable one or more times in whole or in part, to purchase up to an additional 102,272 shares of our common stock on the same terms as the other shares being purchased by the underwriter from us, less underwriting discounts and commissions to cover over-allotments, if any. The underwriter may exercise the option solely for the purpose of covering over-allotments, if any, in connection with this offering. Any shares issued or sold under the option will be issued and sold on the same terms and conditions as the other shares that are the subject of this offering.

Underwriter’s Compensation

Except as disclosed in this prospectus supplement, the underwriter has not received and will not receive from us any other item of compensation or expense in connection with this offering considered by the Financial Industry Regulatory Authority, Inc. (“FINRA”), to